

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/064738 A3

(51) International Patent Classification⁷: **C07D 211/06**,
A61K 31/4468, A61P 25/14, 25/16, 25/18, 25/28, 25/24,
25/06

(21) International Application Number:

PCT/US2004/001234

(22) International Filing Date: 15 January 2004 (15.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/441,406 16 January 2003 (16.01.2003) US
60/479,346 17 June 2003 (17.06.2003) US

(71) Applicant (for all designated States except US): **ACADIA PHARMACEUTICALS INC.** [US/US]; 3911 Sorrento Valley Blvd., San Diego, CA 92121-1402 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WEINER, David, M.** [US/US]; 4915 Muir Avenue, San Diego, CA 92107 (US). **DAVIS, Robert, E.** [US/US]; 13272 Glencliff Way,

San Diego, CA 92130 (US). **BRANN, Mark, R.** [US/US]; 2950 Racetrack View Drive, Del Mar, CA 92014 (US).


(74) Agent: **HART, Daniel**; Knobbe, Martens Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES



(57) Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT_{2A/2C} receptor inverse agonist, demonstrate *in vivo* efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT_{2A/2C} receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

WO 2004/064738 A3



Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

25 November 2004